Curriculum vitae grant James Anhalt, M. D. Address

Download 81.84 Kb.
Size81.84 Kb.
  1   2

Grant James Anhalt, M.D.
ADDRESS: Office: Johns Hopkins Hospital

600 N. Wolfe Street

Blalock 918

Baltimore, Maryland 21287


High School: St. Paul's High School

Winnipeg, Manitoba, Canada

1965 - 1969

Undergraduate: University of Manitoba

Winnipeg, Manitoba, Canada

Faculty of Science, 1969 - 1971

Medical School: University of Manitoba

Winnipeg, Manitoba, Canada

Medicine, July 1971 - June 1975

July 1975 - June 1976: Internship - Rotating

Health Sciences Center

Winnipeg, Canada

July 1976 - June 1977: Residency in Internal Medicine

Health Sciences Center

Winnipeg, Canada

July 1977 - June 1979: Residency in Dermatology

Department of Dermatology

University of Michigan

Ann Arbor, Michigan, U.S.A.

July 1979 - June 1980: Chief Resident

Department of Dermatology

University of Michigan
July 1980 - July 1981: Fellow in Immunodermatology

University of Michigan Medical Center

Ann Arbor, Michigan
July 1981 - August 1982: Instructor, Department of Dermatology

University of Michigan

Ann Arbor, Michigan

September 1982 - May 1987: Assistant Professor,

Director, Resident Training Program,

Department of Dermatology

Johns Hopkins University

May 1987 - May 1993: Associate Professor

Director, Dermatology, Allergy, and

Clinical Immunology Laboratory

Department of Dermatology

The Johns Hopkins University

Baltimore, Maryland, 21205
June 1993 - Dec 1996: Professor, Department of Dermatology

Professor of Pathology

The Johns Hopkins University School of Medicine

Baltimore, Maryland, 21205

- Director, Dermatologic Immunology Laboratory
Jan 1996 - June 2001 Interim Chairman, Dept. of Dermatology

July 2001 - Current

Professor of Dermatology and Pathology

The Johns Hopkins University School of Medicine

Baltimore, Maryland, 21205

July 1980 - July 1981: Attending Physician in Dermatology

VA Medical Center

Ann Arbor, Michigan
Jan 1995 - present:

Medical Advisory Board

The International Pemphigus & Pemphigoid Foundation

Berkeley, California

CERTIFICATION & LICENSURE: -Medical Council of Canada, 1975

-Diplomate of the National Board of Medical Examiners

(U.S.A.), 1978

-Fellow of the Royal College of Physicians and Surgeons of Canada, (Dermatology) 1980

-American Board of Dermatology, 1980

-American Board of Dermatology, Dermatologic Immunology, Diagnostic and Laboratory Immunology, 1987

-Currently licensed to practice in the State of Maryland
PROFESSIONAL SOCIETIES: American Society for Clinical Investigation

American Federation for Medical Research

Society for Investigative Dermatology

American Academy of Dermatology

American Dermatologic Association

Corresponding Member, Austrian Dermatological Society

Dermatology Foundation

Maryland Dermatological Society

EDITORIAL BOARDS: Journal of Investigative Dermatology, June 1992 - 2006
NIH COMMITTEES: Member, NIAMSD Liason Committee, 1993 - 1998.
Intramural Research Programs Review Committee, Dermatology Branch, NCI, 1997.


JHH Physician Advisor - Department of Dermatology, 1995- 1997.

Regulatory Compliance Committee (JCAHO), Johns Hopkins Hospital, 1994 - 1997.
Medical Staff Conference Committee

Johns Hopkins Hospital, July 1988 - 1996.

GRANT REVIEW COMMITTEES: (NIH) Member of Ad Hoc and Special Emphasis Study Sections, Site Visits and Reviewer Reserve, NIAMS, General Medicine A-1 and General Medicine A-2, 1986 - current.
(VA) Veterans Administration ad hoc Reviewer for Merit Awards, 1989 - present.
(Foundations) Dermatology Foundation, National Medical and Scientific Grants Committee, 1989-1992.

GRANT SUPPORT: Veterans Administration Research Career Development Award - Grant Anhalt, P.I. (Associate Investigator), August, 1981, Total direct costs: $103,144.00.
Biomedical Research Council of the University of Michigan. October, 1981, Total award, $5,800.00
Millipore Equipment Grant, Jan. 1989, $6,180.
Andrew W. Mellon Foundation Award, July 1984 - June 1985, Total award, $35,000.00
Stetler Research Foundation (Judy Redd, M.D., P.I. - Grant J. Anhalt, M.D., preceptor) July 1990, $21,000.
NIH - New Investigator Award R23-AM 32490 (00-03), Grant Anhalt, P.I. July 1983 - June 1986, Total direct costs: $108,336.00
NIH - RO1-AM 32490 (04-08), July 1986 - June 1991, Grant Anhalt, P.I., Total direct costs: $250,703.00

NIH - KO4-AR01686 (RCDA) Dec. 1986 - Dec. 1991, Grant Anhalt, P.I., Total direct costs: $270,000.00

Behringwerke AG, Grant Anhalt, P.I., Testing recombinant plasminogen activator inhibitor in pemphigus vulgaris in vivo, Direct costs, $15,800.00, Nov. 1991 - Dec. 1992.
NIH - RO1-AR40018 (01-03) Sept 1991 - Dec.1994, Grant Anhalt, P.I., Total direct costs $325,000.00
NIH - RO1-AR32490 (09-11) July 1991 - June 1994, Grant Anhalt, P.I., Total direct costs $470,000.
NIH-RO1-AI 48063, Pathophysiology of pemphigus in vivo

Grant Anhalt, PI, Sept 2000 - Sept. 2003, total direct costs $525,000


Peptimmune Inc. An open-label, dose escalation, phase I study to assess the safety of PI-0824 in patients with pemphigus vulgaris. Sept 2003 - Feb 2005, Grant Anhalt, PI, direct costs $75,600

Aspreva Pharmaceuticals. A prospective, randomized, double blind, placebo controlled, parallel group, multicenter, 52 week trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to achieve remission in subjects with active pemphigus vulgaris. Aug 2005, Grant Anhalt, PI, direct costs $57,600

Yuzo Takahashi, M.D., Ph.D. Nara University, Japan (1/1/83-12/31/83)

Diya F. Mutasim, M.D. American University, Beirut, Lebanon (4/1/83-12/31/85)

Justin T. Roscoe, M.D. University of Sao Paulo, Brazil (7/1/83-6/30/85)

Fred Eaglstein, D.O. University of Tennessee College of Medicine (7/1/83-7/30/84)

Esperanza Avalos, M.D. Universidad Autonoma de Zacateca (7/1/83-7/30/84)

Hiroshi Hosokawa, M.D. Kansai Medical University, Japan (1/8/85-12/31/86)

Kayo Hosokawa, M.D. Kansai Medical University, Japan (1/8/85-12/31/86)

Elizabeth Dugan, M.D. University of South California (7/1/85-6/30/86)

Luis H. Squiquera, M.D. University of Buenos Aires, Argentina (7/1/85-6/30/87)

Lynne Morrison, M.D. University of Oregon (8/1/86-7/31/88)

Shozo Futamura, M.D. Kansai Medical University, Japan (1/1/87-12/31/89)

Barbara Rock, M.D. Johns Hopkins University (7/1/87-6/30/89)

Mary A. Robledo, M.D. Universidad de Antioquia, Colombia (1/1/88-12/31/90)

Soo Chan Kim, M.D. Yonsei University, Seoul, Korea (10/88-9/90)

Hiroshi Izumi, M.D. Kansai Medical University, Japan, (10/89-6/91)

Judy Redd Oursler, M.D. Johns Hopkins University. (7/90-6/91)

Lena Abdo, M.D. American University of Beiruit. (11/89-11/90)

Kazumi Takehara, M.D. Keio University (7/23/91-6/12/92)

Josiane Hilu, M.D. American University of Beiruit (11/1/91-12/31/93)

Dagmar Födinger, M.D. University of Vienna, Austria (7/1/93-9/30/93)

Jill Albritton, M.D. Johns Hopkins University (7/1/93-6/30/94)

Hossein Nousari, M.D. Cordoba University, Argentina (1/1/95-6/30/95)

Kanokvalai Kulthanan, M.D. Bangkok, Thailand (3/1/98 - 6/30/98)

Hana Jedlickova, MD Olga Havel Foundation Fellow (3/1/99 - 6/1/99)

Patricia Ng, MD National Skin Center Singapore (3/00 - 11/00)

Daniel Mimouni, MD Tel Aviv University (7/01 - 6/02)

Davis Farvolden, MD Johns Hopkins University (7/02 - 6/03)
POSTGRADUATE COURSES: - Molecular Biology. Catholic University, Washington, D.C., 1987.

- The Business of Medicine, for M.Sc. in Business Administration, Johns Hopkins University, 1994 - 1997.

PATENTS AND INVENTIONS: U.S. Patent Serial# 07/400,657, "Suppression of cutaneous contact sensitivity by calcium transport inhibition". Anhalt GJ and Diezel W, Co-Inventors. Licensed to DeNovo, Inc, 1994.
Awards: American Academy of Dermatology Silver Medal for Original Investigations: Dec, 1990
Best Doctors in America, Woodward White, 1994 - current

America’s Top Docs, Castle Connely Guide, 2001 - current

Top Docs, Baltimore Magazine, Oct. 2002 ,Oct 2013
Top Docs, Washingtonian Magazine, 2004 & 2007
American Skin Association Award for Research in Inflammatory Skin Diseases, May, 2002
International Pemphigus Foundation Award for Outstanding Service, Sept 2004
SuperDoctors, Washington Post Magazine , 2011, 2012,2013


  1. Anhalt GJ and Snelling CFT: Toxic Epidermal Necrolysis. Plastic and Reconstructive Surgery, 61:905-910, 1978.

  2. Anhalt GJ, Bahn CF, Labib RS, Voorhees JJ, Sugar A and Diaz LA: Pathogenic effects of bullous pemphigoid autoantibodies on rabbit corneal epithelium. J Clin Invest, 68:1097-1101, 1981.

  3. Cowen SJ, Anhalt GJ, Wicha MS, Sugar A, Labib RS and Diaz LA: Distribution of pemphigus and pemphigoid antigens, laminin and type IV collagen in corneal epithelium. Invest Ophth Vis Sci, 21(6):879-882, 1981.

  4. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF and Diaz LA: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. New Engl J Med, 306:1189-1196, 1982.

  5. Anhalt GJ, Patel HP and Diaz LA: Mechanisms of immunological injury: Pemphigus and pemphigoid. (Editorial) Arch Dermatol, 119:711-714, 1983.

  6. Woo TW, Hogan VA, Patel HP, Anhalt GJ, Labib RS, Voorhees JJ and Diaz LA: Specificity and inhibition of the epidermal cell detachment induced by pemphigus IgG in vitro. J Invest Dermatol, 81:115-121, 1983.

  7. Robinson HN, Anhalt GJ, Patel HP, Takahashi Y, Labib RS and Diaz LA: Pemphigus and pemphigoid antigens are expressed in human amnion epithelium. J Invest Dermatol, 83:234-237, 1984.

  8. Avalos E, Patel H, Anhalt GJ, Diaz LA: Autoimmune injury of squamous epithelium by pemphigus antibodies. Br J Dermatol, III:359-365, 1984.

  9. Takahashi Y, Patel HP, Labib RS, Diaz LA and Anhalt GJ: Experimentally induced pemphigus vulgaris in neonatal BALB/c mice: A time course study of clinical, immunologic, ultrastructural and cytochemical changes. J Invest Dermatol, 84(1):41-46, 1985.

  10. Patel HP, Diaz LA, Anhalt GJ, Labib RS and Takahashi Y: Demonstration of pemphigus antibodies on the cell surface of murine epidermal cell monolayers and their internalization. J Invest Dermatol, 83(6):409-415, 1984.

  11. Mutasim DF, Takahashi Y, Labib RS, Anhalt GJ, Patel HP and Diaz LA: A pool of bullous pemphigoid antigen(s) is intracellular and associated with the basal cell cytoskeleton-hemidesmosome complex. J Invest Dermatol, 84(1):47-53, 1985.

  12. Labib RS, Anhalt GJ, Patel HP and Diaz LA: Epidermal proteins: I. Differential extraction and quantitative polyacrylamide gel-electrophoretic analysis of basal and spinous-cell proteins of neonatal mouse epidermis. Arch Dermatol Res, 277:253-263, 1985.

  13. Unis ME, Pfau RG, Patel H, Takahashi Y, Anhalt GJ: An acquired form of epidermolysis bullosa without immunoreactants. J Am Acad Dermatol, 13(2):377-380, 1985.

  14. Takahashi Y, Mutasim DF, Patel HP, Anhalt GJ, Labib RS and Diaz LA: The use of human pemphigoid autoantibodies to study the fate of epidermal basal cell hemidesmosomes after trypsin dissociation. J Invest Dermatol, 85:309-313, 1985.

  15. Roscoe JT, Diaz LA, Sampaio APS, Castro RM, Labib RS, Takahashi Y, Patel HP and Anhalt GJ: Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol, 85:538-541, 1985.

  16. Anhalt GJ, Patel HP, Labib RS, Diaz LA and Proud DA: Dexamethasone inhibits plasminogen activator activity in experimental pemphigus in vivo but does not block acantholysis. J Immunol, 136:113-117, 1986.

  17. Labib RS, Anhalt GJ, Patel HP, Mutasim DF and Diaz LA: Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol, 136(4):1231-1235, 1986.

  18. Roscoe JT, Naylor PH, Diaz LA, Labib RS, Patel HP, Goldstein AL, Sampaio SAP and Anhalt GJ: Elevated thymosin alpha one levels in Brazilian pemphigus foliaceus. Br J Dermatol, 115:147-150, 1986.

  19. Anhalt GJ, Till GO, Diaz LA, Labib RS, Patel HP, and Eaglstein NF. Defining the role of complement in experimental pemphigus in mice. J Immunol, 137:2835-2840, November, 1986.

  20. Diaz LA, Anhalt GJ, Hosokawa H, and Takahashi Y. Bullous pemphigoid antigens. Keio Journal of Medicine, (Japan) 35:69-79, 1986.

  21. Mutasim D, Anhalt GJ, Diaz LA, and Patel HP. Linear immunofluorescence staining of the cutaneous basement membrane zone produced by pemphigoid antibodies: The result of hemidesmosome staining. J Amer Acad Dermatol, 16:75-82, 1987.

  22. Katz R, Hood AF, Anhalt GJ. Captopril-induced pemphigus-like eruption. (Letter) Arch Dermatol, 123:20-21,1987.

  23. Livingston JZ, Scott TE, Wigley FM, Anhalt GJ, Bias WB, McLean RH, and Hochberg MC. Systemic sclerosis (Scleroderma): Clinical, genetic and serologic subsets. J Rheumatol, 14:512-518, 1987.

  24. Zebede MS, Anhalt GJ, Nsouli TM, Nsouli SM, and Bellanti JA. Diffuse bullous eruption in a 3 month old infant. Ann Allergy, 58(1), 12-13 and 63-66, 1987.

  25. Anhalt GJ, Jampel HD, Patel HP, Diaz LA, Jabs DA, and Mutasim DF. Bullous pemphigoid autoantibodies are markers of corneal epithelial hemidesmosomes. Invest Ophth Vis Sci, 28:903-907, 1987.

  26. Rowinsky EK, McGuire WP, Anhalt GJ, Ettinger DS, and Donehower RC. Hexamethylene bisacetamide (HMBA) - induced cutaneous vasculitis. Cancer Treatment Reports, 71:471-474, 1987.

  27. Diaz LA, Sampaio SAP, Rivitti EA, Macca ML, Roscoe JT, Takahashi Y, Labib RS, Patel HP, Mutasim DF, Dugan EM and Anhalt GJ: An autoantibody in pemphigus serum specific for the 59 kD keratin selectively binds the surface of keratinocytes: Evidence for an extracellular keratin domain. J Invest Dermatol, 89:287-295, 1987.

  28. Matis W, Anhalt GJ, Martins C, Diaz LA, and Berger R. Calcium enhances the sensitivity of immunofluorescence for pemphigus antibodies. J Invest Dermatol, 89:302-304, 1987.

  29. Anhalt, GJ: Autoantibodies and cell-to-cell detachment in pemphigus. (Editorial) J Lab Clin Med, Vol. 3, No. 1:13-14, 1988.

  30. Morrison L, Labib RS, Zone JJ, Diaz LA, and Anhalt GJ. Herpes gestationis autoantibodies recognize a 180kD epidermal antigen. J Clin Invest, 81:2023-2026, 1988.

  31. Mutasim DF, Morrison LH, Takahashi Y, Labib RS, Skouge J, Diaz LA, and Anhalt GJ: Definition of bullous pemphigoid antibody binding to intracellular and extracellular antigen associated with hemidesmosomes. J Invest Dermatol, 92:225-230, 1989.

  32. Diaz LA, Sampaio SAP, Rivitti EA, Martins CR, Cunha PR, Lombardi C, Almeida FA, Martins-Castro R, Macca ML, Lavrado C Filho GH, Borges PC, Chaul A, Minelli L, Empinotti JC, Friedman H, Campbell I, Labib RS, and Anhalt GJ: Endemic Pemphigus Foliaceus (Fogo Selvagem): II. Current and Historic Epidemiologic Studies. J Invest Dermatol, 92:4-12, 1989.

  33. Squiquera HL, Diaz LA, Sampaio SAP, Rivitti EA, Martins CR, Cunha PR, Lombardi C, Lavrado C Filho GH, Borges PC, Friedman H, Labib RS, Anhalt GJ and the Cooperative Group On Fogo Selvagem Research: Serological Abnormalities in Patients with Endemic Pemphigus Foliaceus (Fogo Selvagem), their Relatives and Normal Donors from Endemic and Non-Endemic Areas. J Invest Dermatol, 91:189-191, 1988.

  34. Diaz LA, Sampaio SAP, Rivitti EA, Martins CR, Cunha PR, Lombardi C, Almeida FA, Martins-Castro R, Macca ML, Lavrado C Filho GH, Borges PC, Chaul A, Minelli L, Empinotti JC, Friedman H, Campbell I, Labib RS, and Anhalt GJ: Endemic Pemphigus Foliaceus (Fogo Selvagem): I. Clinical Features and Immunopathology. J Amer Acad Dermatol, 20:657-669, 1989.

  35. Diezel VW, Gruner S, Anhalt GJ, Strunk D, Shanks M, Sönnichsen N: Kontaktüberempfindlichkeit (DNCB-test) und hemmung durch den calcium-kanal-blocker diltiazem. Dermatol Mon-schr, 175:170-174, 1989.

  36. Rock B, Martins CR, Theofilopoulos AN, Balderas RS, Anhalt GJ, Labib RS, Futamura S, Rivitti EA, and Diaz LA: The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus. New Eng J Med, 320:1463-1469, 1989.

  37. Diezel W, Gruner S, Diaz LA, and Anhalt GJ. Inhibition of cutaneous contact hypersensitivity by calcium transport inhibitors lanthanum and diltiazem. J Invest Dermatol, 93:322-326, 1989.

  38. Labib RS, Camargo S, Futamura S, Martins C, Rock B, Anhalt GJ, Diaz LA: The pemphigus foliaceus antigen: Characterization of a keratinocyte envelope associated pool and preparation of a soluble immunoreactive fragment. J Invest Dermatol, 93:272-279, 1989.

  39. Futamura S, Martins CR, Rivitti EA, Labib RS, Diaz LA, Anhalt GJ. Ultrastructural studies of acantholysis induced in vivo by passive transfer of IgG from endemic pemphigus foliaceus (fogo selvagem). J Invest Dermatol, 93:480-485, 1989.

  40. Yokel BK, Hood AF, Anhalt GJ: Induction of Acantholysis in Organ Explant Culture by D-penicillamine and Captopril. Arch Dermatol 125:1367-1370, 1989.

  41. Joyce AP, Horn TD, and Anhalt GJ: Prurigo Pigmentosa: A case report and review of the literature. Arch Dermatol, 125:1551-1554, 1989.

  42. Dugan EM, Labib RS, Anhalt GJ and Diaz LA: Selective Surface Radioiodination of Keratinocytes in Primary Culture Labels a 59 kD Keratin and Other Surface Proteins. Arch Derm Res, 281:463-469, 1989.

  43. Moran KT, Anhalt GJ, O'Reilly TJ, Thupari JN, and Munster AM: Autoantibody formation in burn patients after inhibition of suppressor T cell activity with Polymyxin B. J Burn Care & Rehab, 10:213-215, 1989.

  44. Gruner S, Diezel W, Strunk D, Zwirner A, Sönnichsen, Anhalt GJ: Stimulation of the recruitment of epidermal Langerhans cells by splenopentin. Arch Dermatol Res, 281:526-529, 1990.

  45. Robledo MA, Kim SC, Labib RS, Korman NJ, Stanley JR, Futamura S, and Anhalt GJ. Studies of the relationship of the 230 KD and 180 KD bullous pemphigoid antigens. J Invest Dermatol, 94:908-913, 1990.

  46. Diaz LA, Ratrie H, Saunders W, Futamura S, Squiquera HL, Anhalt GJ, and Guidice GJ. Isolation of a human epidermal cDNA corresponding to the 180 kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest, 86:1088-1094, 1990.

  47. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H, Mutasim D, Ariss-Abdo L, and Labib RS. Paraneoplastic pemphigus: An autoimmune mucocutaneous disease associated with neoplasia: New Engl J Med, 323:1729-1735, 1990.

  48. Anhalt GJ and Morrison LH. Bullous and cicatricial pemphigoid. J Autoimmunity, 4:17-35, 1991.

  49. Morrison LH, and Anhalt GJ. Herpes Gestationis. J Autoimmunity, 4:37-45, 1991.

  50. Diezel W, Gruner S, Strunk D, Eckert, Siems W, and Anhalt GJ. Inhibition of Langerhans cell ATPase and contact sensitization by lanthanides - role of T suppressor cells. J Invest Dermatol, 97:478-482, 1991.

  51. Labib RS, Rock B, Robledo MA, Anhalt GJ. The calcium sensitive epitope of pemphigus foliaceus antigen is present on a murine tryptic fragment and constitutes a major antigenic region for human autoantibodies. J Invest Dermatol, 96:144-147, 1991.

  52. Diezel W, Shanks M, Anhalt GJ. Contact dermatitis - new pathogenetic aspects and suppression by magnesium ions. Z Hautkr, 66(5)436-438, 1991.

  53. Fullerton SH, Woodley DT, Smoller B, Anhalt GJ. Paraneoplastic pemphigus with immune deposits in bronchial epithelium. JAMA, 267(11):1550-1502, 1992.

  54. Diezel W, Gruner S, Anhalt GJ. ATPase-positive epidermal Langerhans cells: Inhibition of the ATPase by ammonium bituminosulfonate (Ichthyol) and Pix lithanthracis. Der Hauzarzt, 43:22-24, 1992.

  55. Oursler J, Ariss-Abdo L, Labib RS, O'Keefe E, Burke T, Anhalt GJ. Human autoantibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest, 89:1775-1782, 1992.

  56. Horn TD and Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol, 128(8):1091-1095, 1992.

  57. Finzi E, Ho T, Anhalt GJ, Hawkins W, Harkins R, Horn T. Localization of TGF- in human appenageal tumors. Am J Pathol, 141:643-653, 1992.

  58. Labib RS, Izumi H, Santana H, Rock B, and Anhalt GJ. Purification of immunoprecipitated pemphigus foliaceus antigen fragment and its use in radioimmunoassay. J Invest Dermatol, 99:819-834, 1992.

  59. Siegel MS, Anhalt GJ. Direct immunofluorescence of detached gingival epithelium for diagnosis of cicatricial pemphigoid: report of five cases. Oral Surg Oral Med Oral Path, 75:296 - 302, 1993.

  60. Jabs EW, Tuck-Muller C, Anhalt GJ, Earnshaw W, Wise RA, and Wigley F. Cytogenetic survey in systemic sclerosis: correlation of aneuploidy with the presence of anticentromere antibodies. Cytogenetics and Cell Genetics, 63:169-175, 1993.

  61. Stevens SR, Griffiths CEM, Anhalt GJ, Cooper, KD. Paraneoplastic pemphigus presenting as a lichen planus pemphigiodes-like eruption. Arch Dermatol, 129:866-869, 1993.

  62. Berg WE, Fishman EK, Anhalt GJ. Retroperitoneal reticulum cell sarcoma: a cause of paraneoplastic pemphigus. Southern Med J, 86(2):249-250, 1993.

  63. Fried RG, Lynfield Y, Vitale P, Anhalt GJ. Paraneoplastic pemphigus appearing as bullous pemphigoid-like eruption after palliative radiation therapy. J Amer Acad Dermatol, 29(5):815-817, 1993.

  64. Mehregan DR, Oursler JR, Leiferman KM, Muller SA, Anhalt GJ, Peters MS. Paraneoplastic pemphigus: a subset of patients with pemphigus and neoplasia. J Cutan Pathol, 20:203-210, 1993.

  65. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol, 151:1-9, 1993.

  66. Giudice GJ, Wilske K, Anhalt, GJ, Fairley JA, Taylor AF, Emery DJ, Hoffman RG, Diaz LA. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol. 102:878-881, 1994.

  67. Domloge-Hultsch N, Anhalt GJ, Gammon WR, Lazarova Z, Briggaman R, Welch M, Jabs DA, Huff C, Welch M, Yancey KB. Anti-epiligrin cicatricial pemphigoid: A subepithelial bullous disorder of mucous membranes. Arch Dermatol. 130:1521 - 1529, 1994.

  68. Christiano AM, Anhalt GJ, Gibbons S, Bauer EA, Uitto J. Premature termination codons in the type VII collagen gene (COL7A1) underlie the severe, mutilating (Hallopeau-Siemens) type of recessive dystrophic epidermolysis bullosa. Genomics. 21(1):160-168, 1994.

  69. Casciola-Rosen LA, Anhalt GJ, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med, 179:1317-1330, 1994.

  70. Casciola-Rosen LA, Miller DK, Anhalt GJ, Rosen A. Specific cleavage of the 70kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J. Biol. Chem., 269:49;30757 - 30760, 1994.

  71. Foedinger D, Anhalt GJ, Boecskoer B, Elbe A, Wolff K, and Rappersberger K. Autoantibodies to desmoplakin I and II in patients with erythema multiforme. J Exp Med, 181: 169 - 179, 1995.

  72. Helou J, Allbritton J, and Anhalt GJ. Accuracy of indirect immunofluorescent testing in the diagnosis of paraneoplastic pemphigus. J Amer Acad Dermatol,32:441-447, 1995.

  73. Kirsner, RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Brit. J. Dermatol. 132: 474-478, 1995.

  74. Ståhle-Backdähl M, Hedblad MA, Skoglund C, Fagerholm P, Anhalt GJ. Paraneoplastic pemphigus: A report of two patients responding to cyclosporine. Eur J Dermatol. ,5: 671 - 675, 1995.

  75. Williams MA, Dowling PM, Angarano DW, Yu AA, DiFranco BJ, Lenz SD, Anhalt GJ. Paraneoplastic bullous stomatitis in a horse. J Am Vet Med Assoc. 207 (3): 331-334, 1995.

  76. Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman's tumor. Dermatology 190(3): 245 - 250, 1995.

  77. Casciola-Rosen, Anhalt GJ, Rosen A. DNA-Dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J. Exp. Med. 182: 1625 - 1624, 1995.

  78. Foedinger D, Sterniczky B, Elbe A, Anhalt G, Wolff K, Rappersberegr K. Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. J. Invest. Dermatol. 106: 1012 - 1016, 1996.

  79. Gott VL, Laschinger JC, Cameron DE, Dietz HC, Greene PS, Gillinov AM, Pyeritz RE, Alejo DE, Fleischer KJ, Anhalt GJ, Stone CD, McKusick VA. The Marfan Syndrome and the Cardiovascular Surgeon. Eur J Cardio-thorac Surgery. 10: 149 - 158, 1996.

  80. Bialy-Golan A, Brenner S, Anhalt GJ. Paraneoplastic pemphigus: Oral involvement as the sole manifestation. Acta Dermato-Venerologica, 76;3:253 - 254. 1996.

  81. Fleischer KJ, Nousari HC, Anhalt GJ, Laschinger JC. Immunohistochemical abnormalities of fibrillin in cardiovascular tissues in Marfan Syndrome. Ann Thorac. Surg., 63:1012 - 1017, 1997.

  82. Brenner S, Bialy-Golan A, Anhalt GJ. Recognition of pemphigus antigens in drug-induced pemphigus vulgaris and foliaceus. J Amer Acad Dermatol, 36:919-923, 1997.

  83. Chan LS, Majmudar AA, Tran HH, Meier F, Schaumburg-Lever G, Chen M, Anhalt GJ, Woodley DT, Marinkovich MP. Laminin-6 and laminin-5 are co-target antigens in a subset of cicatricial pemphigoid. J. Invest. Dermatol. 108:848-853, 1997.

  84. Whitmore ES, Anhalt GJ, Provost TT, Zacur HA, Hamper UM, Helzsouer KJ, Rosenshein NB. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecologic Oncology, 65: 241-244, 1997.

  85. Allbritton JI, Nousari HC, and Anhalt GJ. Anti-epiligrin (laminin 5) cicatricial pemphigoid. Br. J. Dermatol. 137:992-996, 1997.

  86. Morison W, Anhalt GJ. Therapy with oral psoralen plus UV-A for erythema multiforme (Letter). Arch Dermatol 133;11:1465 - 1466, 1997.

  87. Schlesinger T, McCarron K, Camisa C, Anhalt G. Paraneoplastic pemphigus occurring in a patient with B-cell non-Hodgkin’s lymphoma. Cutis 61;2:94-96, 1998.

  88. Kim SC, Chang SD, Anhalt GJ, Rapk ET, Jeong CW, Lee CW , Ahn CM. Paraneoplastic pemphigus with localized mucosal lesions and severe pulmonary involvement. Br. J. Dermatol, 138; 667 - 671, 1998.

  89. Van der Wall RIF, Pas HH, Anhalt GJ, Schulten EAJM, Jonkman MF and Niebor C. Paraneoplastic pemphigus as the presenting symptom of a lymphoma of the tongue. Oral Oncology, 34: 567-570, 1998.

  90. Nousari HC, Griffin WA, and Anhalt GJ. Successful therpay of bullous pemphigoid with mycophenolate mofetil. J Amer Acad Dermatol, 39:497- 498, 1998.

  91. Mahler V, Antoni C, Anhalt GJ, Koch HJ,Peters KP, Manager B, Kalden JR, Hornstein OP. Graft vs. Host - like mucocutaneous eruptions with serologic features of paraneoplastic pemphigus and systemic lupus erythematosus in a patient with non-Hodgkin’s lymphoma.. Dermatology 197:78-83, 1998.

  92. Nousari HC, Costarangos C, Anhalt GJ. Vancomycin-induced linear IgA bullous dermatosis: an immunologically-mediated drug eruption.(letter) Annals Int Med, 129:507-508, 1998.

  93. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J. Clin Invest, 102:775-782, 1998.

  94. Cohen SS, Hemdier BG, Anhalt GJ, Blauvelt A. No evidence of human herpesvirus 8 infection in patients with paraneoplastic pemphigus, pemphigus vulgaris or pemphigus foliaceus. J. Invest. Dermatol, 111:781-783, 1998.

  95. Nousari HC, Kimyai-Asadi A, Ketabchi N, Hughes M, Anhalt GJ. A patient with a refractory cutaneous bullous eruption. J Cutan Med Surg. 3:201-204, 1999.

  96. Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J. Am. Acad. Dermatol, 40:265-268, 1999.

  97. Nousari HC, Lynch W, Petri M, Anhalt GJ. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch. Dermatol, 134:1509-1511, 1998.

  98. Nousari HC, Rencic A, Hsu R, Yancey KB, Anhalt GJ. Anti-epiligrin cicatricial pemphigoid with antibodies against the gamma-2 subunit of laminin 5. Arch. Dermatol., 135;173-176, 1999.

  99. Nousari HC, Kimyai-Asadi A, Ketabchi N, Diaz LA, Anhalt GJ. Severe non-endemic pemphigus foliaceus presenting in the post-partum period. J. Am. Acad. Dermatol, 40;845-846, 1999.

  100. Schein OD, Hochberg MC, Munoz B, Tielsch JM, Bandeen-Roche K, Provost TT, Anhalt GJ, West S. Dry eye and dry mouth in the elderly: A population based assesment. Arch Int Med, 159:1359-1363, 1999.

  101. Nousari HC, Kimyai-Asadi A, Caeiro JP, Anhalt GJ. Clinical, demographic and immunohistologic features of vancomycin-induced linear IgA bullous disease. Medicine (Baltimore), 78:1-8, 1999.

  102. Sapadin AN, Anhalt GJ. Paraneoplastic pemphigus with a pemphigus vegetans-like plaque as the only cutaneous manifestation. J. Amer. Acad. Dermatol. 39 (5) Part 2:867-871, 1998.

  103. Kiyokawa C, Rurhberg C, Nie Z, Karashima T, Mori O, Nishikawa T, Green KJ, Anhalt GJ, DiColandrea T, Watt F, Hashimoto T. Envoplakin and periplakin are components of the paraneoplastic pemphigus antigen complex. J Invest Dermatol (letter): 111;1236-1238, 1998.

  104. Nousari HC, Anhalt GJ, Diaz LA. Penfigo parneoplastico. Dermatologia Argentina 4:301-310, 1998.

  105. Nousari H, Kimyai-Asadi A, Anhalt GJ. Elevation of serum interleukin-6 levels in paraneoplastic pemphigus. J Invest Dermatol, 112: 396-398, 1999.

  106. de Bruin A, Muller E, Wyder M, Anhalt GJ, Lemmens P, Suter MM. Peri- and envoplakin are target antigens in canine and human paraneoplastic pemphigus. J Amer Acad Dermatol, 40: 682-685, 1999.

  107. Anhalt GJ. Making sense of antigens and antibodies in pemphigus (Editorial). J Amer Acad Dermatol, 40;763-766,1999.

  108. Nousari HC, Deterding R, Wojtczack H, Aho S, Uitto J, Hashimoto T, Anhalt GJ. The mechanism of respiratory failure in paraneoplastic pemphigus. New Engl J Med, 340;1406-1410, 1999.

  109. Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease. J Amer Acad Dermatol. 40: 750 - 754, 1999.

  110. Chorzelski TP, Hashimoto T, Amagai M, Sysa-Jedrzejowska A, Choczaj A, Nousari HC, Anhalt GJ, Jablonska S. Paraneoplastic pemphigus with cutaneous and serologic features of pemphigus foliaceus. Br. J. Dermatol. 141:357-359, 1999.

  111. Nousari HC, Anhalt GJ, Morison WL. Mycophenolate in psoralen-UV_A desensitization therapy for chronic actinic dermatitis. Arch Dermatol. 135: 1128-1129, 1999.

  112. Nousari HC, Anhalt GJ. The role of mycophenolate mofetil in the management of pemphigus.(Letter) Arch Dermatol. 135: 853-854, 1999.

  113. Mascaro JM Jr., Ferrando J, Sole MT, Alsina M, Nousari HC, Anhalt GJ, Font J, Mascaro JM. Paraneoplastic pemphigus: a case of long term survival associated with systemic lupus erythematosus and polymyositis. Dermatology 199:63-66, 1999.

  114. Nousari HC, Goyal S, Anhalt GJ. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil (Letter). Arch Dermatol. 135:1420 - 1421, 1999.

  115. Nousari HC, Anhalt GJ. Pemphigus and Bullous Pemphigoid. The Lancet 354:667-672, 1999.

  116. Anhalt GJ, Nousari HC, Deterding R. The mechanism of respiratory failure in paraneoplastic pemphigus. (Letter). New Engl. J. Med. 341:848, 1999.

  117. Chorzelski T, Hashimoto T, Macciejewska B, Amagai M, Anhalt GJ, Jablonska S. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. J Amer Acad Dermatol. 41: 3; 393-400, 1999.

  118. Sole TM, Ferrando J, Alsina M, Anhalt GJ, Mascaro JM. Long term regression of paraneoplastic pemphigus after surgical excision of associated Castleman's tumor. Dermatol. in press, 2001.

  119. Van der Waal RIF, Pas HH, Nousari HC, Schulten EAJM, Jonkman MF, Nieboer C Starink TM, and Anhalt GJ,. Paraneoplastic pemphigus caused by an epithelioid leiomyosarcoma and associated with fatal respiratory failure. Oral Oncology, 2000, July 1:36;390-393.

  120. Nousari HC, Anhalt GJ. Bullous pemphigoid treated with leflunomide, a novel immunomodulatory agent. Arch Dermatol,2000, 136: 1204 - 1205.

  121. Bowen GM, Peters NT, Fivenson DP, Su LD, Nousari HC, Anhalt GJ, Cooper KD, Stevens SR. Lichenoid dermatitis in paraneopastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol. 2000; 136: 652-656.

  122. Sallout H, Anhalt GJ, Al-Kawas FH. Cicatricial pemphigoid presenting with isolated esophageal involvement: A case report. Gastrointestinal Endoscopy, 2000; 52:429-433.

  123. Geyer AS, Anhalt GJ, Nousari HC. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohns disease. Arch Dermatol. 2000; 136: 459-460.

  124. Abraham SC, Ravich WJ, Anhalt GJ, Yardley JH, Wu TT. Esophageal lichen planus: case report and review of the literature. Am J Surg Path. 2000;24:1678-1682.

  125. Obasanjo OO, Wu P, Conlon M, Karanfil L, Pryor P, Moler G, Anhalt GJ, Chaisson RE, Perl TM. An outbreak of scabies in a teaching hospital., Infection Control and Hospital Epidemiology, 2001;22: 13 - 18.

  126. Nousari HC, Moresi M, Klapper M, Anhalt GJ. Nonendemic pemphigus foliaceus presenting as fatal bullous erythema multiforme. Cutis 67;251 - 252, 2001.

  127. Inaoki M, Kodera M, Fujimoto A, Nousari HC, Anhalt GJ, Takehara K. Paraneoplastic pemphigus without anti-desmoglein 3 or anti-desmoglein 1 antibodies. Br J Dermatol 2001;144:610-613.

  128. Ohyama M, Amagai M, Hashimoto T, Nousari HC, Anhalt GJ, Nishikawa T. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus. J Amer Acad Dermatol, 44;593-598, 2001.

  129. Anhalt GJ, Diaz LA. Prospects for autoimmune disease:Research Advances in Pemphigus. JAMA 2001; 285:652-654.

  130. Anhalt GJ. Paraneoplastic pemphigus: the role of tumors and drugs. (Editorial) Br J Dermatol, 144; 1101-1104, 2001.

  131. Brenner S,Tur E, Shapiro J, Ruocco V, D’Avino M, Ruocco E, Tsankov N, Vassileva S, Drenovska K, Bresoev P, Barnadas M, Gonzales M, Anhalt GJ, Nousari H, Ramos e Silva M, Pinto K, Miranda M. Pemphigus vulgaris: environmental factors, occupational, behavioural, medical and qualitative food frequency questionnaire. Int. J. Dermatol., 40;562-569, 2001

  132. Nousari HC, Kimyai-Asadi A, Anhalt GJ. Chronic idiopathic acrocyanosis. J Am Acad Dermatol. 45:S207-208, 2001.

  133. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic features, medical treatment and prognostic indicators. Arch Dermatol. 138: 370-379, 2002.

  134. Mutasim DF, Anhalt GJ. Bullous diseases in the eldely. Clin Geriatr Med. 18:43-58, 2002.

  135. Mimouni D, Anhalt GJ, Lazarova Z, Aho S, Kazerounian S, Kouba DJ, Mascaro JM, Nousari HC. Paraneoplastic pemphigus in children and adolescents. Br. J. Dermatol. 147;725-732, 2002.

  136. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, Ha E, Anhalt GJ, Provost T, Nousari HC. Drug-induced Ro/SSA positive cutaneous lupus erythematosus. Arch Dermatol, 139;45-49, 2003.

  137. Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br. J. Dermatol. 148:813-816, 2003.

  138. Yoo SS, Tran M, Anhalt GJ, Barrett T, Vonderheid EC. Disseminated cryptococcis in the setting of prednisone monotherpay for pephigus vulgaris. J Dermatol. 30:405-410, 2003.

  139. Nikolskaia OV, Nousari HC, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman’s disease. Br. J. Dermatol., 149:1143-51, 2003.

  140. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne J, Nousari HC. Treatment of pemphigus vulgaris and foliaceus with mycophenolate mofetil. Arch Dermatol., 139:739-742, 2003.

  141. Nousari HC, Brodsky R, Anhalt GJ. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol. 49:148-150, 2003.

  142. Thorne JE, Jabs DA, Nikolskaia O, Anhalt GJ, Nousari HC. Discoid lupus erythematosus and cicatrizing conjunctivitis: clinicopathologic study of two cases. Ocul Immunol Inflamm 10:287-292, 2002.

  143. Hoffman MA, Qiao X, Anhalt GJ. CD8+ T lymphocytes in bronchiolitis obliterans, paraneoplastic pemphigus and solitary Castleman’s disease. New Engl J Med. 349:407-408, 2003.

  144. Thorne JE, Jabs DA, Nikolskaia O, Mimouni D, Anhalt GJ, Nousari HC. Lichen planus and cicatrizing conjunctivitis: characterization of five cases. Am J Ophth. 136:239-243, 2003.

  145. Cummins DL, Mimouni D, Anhalt GJ, Nousari HC. Oral cyclophosphamide for the treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol. 49:276-280, 2003.

  146. Geyer AS, Zillikens D, Skrobek C, Cohen B, Anhalt GJ, Nousari HC. Vesicular pemphigoid in a 16 year old boy. J Am Acad Dermatol. 49:722-724, 2003.

  147. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD 20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol, 2:564-7, 2003

  148. Mimouni D, Nousari HC, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol. 49:1059-1062, 2003.

  149. Ahmed AR, Dahl MV et al. Consensus statement on the use of innravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch. Dermatol. 139;1051-1059, 2003

  150. Anhalt GJ. Paraneoplastic pemphigus. J Invest Dermatol Symp Proc. 2004:9; 29-33.

  151. Mimouni D, Foedinger D, Kouba DJ, Orlow SJ, Rappersberger K, Sciubba JJ, Nikolskaia O, Cohen BA, Anhalt GJ, Nousari HC. Mucosal dominant pemphigus vulgaris with anti-desmoplakin antibodies. J Am Acad Dermatol, 51: 62-67, 2004.

  152. Thorne JE, Anhalt, GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology 111:45-52, 2004.

  153. Anhalt GJ. Paraneoplastic Pemphigus. J Invest Dermatol. Symp Proc. Jan 9 (1):29-33, 2004.

  154. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 40: 553-62, 2004.

  155. Anhalt GJ, Diaz LA. Pemphigus vulgaris - a model for cutaneous autoimmunity. J Am Acad Dermatol. July 2004, Supp, S20-21.

  156. Mimouni, D, Foedinger, Anhalt GJ, Nousari CH, et al. Mucosal dominant pemphigus vulgaris with anti-desmoplakin antibodies. J Am Acad Dermatol. July 2004 ; 51:62-67.

  157. Elmore SA, Basseches J, Anhalt GJ, Cullen, JM, Olivry T. Paraneoplastic pemphigus in a dog with splenic sarcoma. Vet Pathol, 2005; 42: 88-91.

  158. Goldstein AT, Anhalt GJ, Klingman D, Burrows, LJ. Mucous membrane pemphigoid of the vulva. Obstet Gynecol 2005, 105; 1188-1190.

  159. Mimouni D, Blank M, Ashkenazi L, Milner Y, Frusic-Zlotkin M, Anhalt GJ, David M. Protective effect of intravenous immunoglobulin in an experimental model of pemphigus vulgaris. Clin Exp Immunol. 2005: 142; 426-32.

  160. Santi CG, Flores RS, Medina MM, Maruta CW, Aoki V, Anhalt GJ, Rivitti EA. Paraneoplastic pemphigus associated with pelvic inflammatory fibrosarcoma: a case report. J Dermatol. 2005:32; 1014-20.

  161. Tran MM, Anhalt GJ, Barrett T, Cohen BA. Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent. J Amer Acad. Dermatol. 2006:54; 734-6.

  162. Scherr N, Anhalt GJ, Wigley F. Bullous pemphigoid in a patient with scleroderma. J. Rheum. 2006, 10: 2098

  163. Olivia-Hemker M, Berkenblit GV, Anhalt GJ, Yardley JH. Pernicious anemia and widespread abscence of gastrointestinal endocrine cells in a patient with Autoimmune Polyglandular Syndrome Type I and malabsorption. J Clin Endocrine Metab. 91(8):2833-2838, 2006

  164. Thorne JE, Anhalt GJ, Jabs DA, de la Cruz Z, Green WR. Role of electron microscopy in the diagnosis of ocular mucous membrane pemphigoid. Ophthalmology 2006;113:1651-1656.

  165. Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006, 20:5:e8

  166. Cummins DL, Mimouni D, Tzu J, Owens N, Anhalt GJ, Meyerle JH. Lichenoid Paraneoplastic pemphigus in the absence of detectable autoantibodies. J Amer Acad. Dermatol. 2007:1; 153-9.

  167. Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ. Rituximab therapy in severe juvenile pemphigus vulgaris. Cutis 2007;80; 335 – 340.

  168. Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. H Br J Dermatol. 2007 : 157; 1235 - 1239.

  169. Hosler, GA, Leigeois N, Anhalt GJ, Moresi JM. Transformation of gamma/delta T cell lymphoma following 15 years of indolent behavior. J Cutaneous Pathology. 2008: 35; 1063-1067.

  170. Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 2008: 115; 2146 – 2152.

  171. Stefan Beissert1, Daniel Mimouni2, Amrinder Jit Kanwar3, Neil Solomons4, Veena Kalia4, Grant Anhalt5. Treating Pemphigus Vulgaris with Prednisone and Mycophenolate Mofetil: A Multicenter, Randomized, Placebo-Controlled Trial .J.Invest.Dermatol Aug; 130 (8) : 2041-8, 2010

  172. Mimouni, M. Blank, A.S. Payne, G.J. Anhalt, C. Avivi, I. Barshack, M. David, Y. Shoenfeld. Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol. 2010:162(3); 543-549

  173. Amato AA and members of the Muscle Study Group. A randomized, pilot trial of etanercept in Dermatomyositis. Ann Neurol, 70(3):427-436, 2011

  174. DeZern, ………… Anhalt GJ, et al. High dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore), 90(2): 89-98, 2011.

  175. Leshem Y, Hodak E, David M, Anhalt GJ Mimouni D. Successful treatment of pemphigus with bi-weekly one gram infusions of rituximab: a retrospective study of 47 patients. J Amer Acad Dermatol, 68:404-411, 2013

  176. Kalantari-Dehaghi M, Anhalt GJ, et al.. Pemphigus vulgaris autoantibody profiling by proteomic technique. PLoS One 2013;8(3):e57587

Share with your friends:
  1   2

The database is protected by copyright © 2019
send message

    Main page